Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26632997 | 0.89 | ADORA2A (0.51) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL7011406 | 0.89 | ADORA2A (0.70) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL161948 | 0.89 | L3MBTL1 (0.60) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL19924520 | 0.87 | ADORA2A (0.52) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL935583 | 0.81 | ADORA2A (0.61) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL245321 | 0.81 | ADORA2A (0.60) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL15286644 | 0.80 | ADORA1 (0.60) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL4436700 | 0.78 | ADORA2A (0.60) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL3548799 | 0.78 | KDM4E (0.49) | ADORA2AHSD17B10ADRA2AHTTKDM4E | |
| SCHEMBL28383673 | 0.78 | KDM4E (0.66) | ADORA2AHSD17B10ADRA2AHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | disclosed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | disclosed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | disclosed |
| EP-4153299-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Rodeo Therapeutics Corporation (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021236779-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021236779-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION (US) | 2021-11-25 | — | — | WO | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| US-7855219-B2 | Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-21 | — | — | US | disclosed |
| EP-1368320-B1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-20050261502-A1 | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1368320-A1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-12-10 | — | — | EP | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002070484-A1 | SUBSTITUTED 2-OXY-3,5-DICYANO-4-ARYL-6-AMINOPYRIDINES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | ADORA2A 1966/4885HSD17B10 21/4885ADRA2A 1968/4885 |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | ADORA2A 2417/4885HSD17B10 3642/4885ADRA2A 847/4885 |
| US-20050261502-A1 | Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885HSD17B10 3538/4885ADRA2A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.